AdAlta Limited (ASX:1AD) is a listed, clinical stage drug discovery and development company headquartered in Melbourne, Australia.
AdAlta’s proprietary i-body technology platform is being used to solve challenging drug targeting problems, generating a new class of single domain antibody protein therapeutics with the potential to treat some of today’s most challenging medical conditions. The i-body technology mimics the shape and stability of a unique and versatile antigen-binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with important but previously difficult to access targets such as G-protein coupled receptors (GPCRs). AdAlta’s i-bodies are the first fully human single domain antibodies and the first single domain antibodies utilising the shark motif to reach clinical trials.
AdAlta’s strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates, primarily against GPCRs implicated in fibrosis, inflammation and cancer; and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.
AD-214 is AdAlta’s lead i-body enabled internal pipeline candidate and is currently in Phase 1 clinical trials. AD-214 is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high unmet medical need.
AdAlta’s external pipeline collaborations include an agreement with GE Healthcare to discover i-bodies as diagnostic imaging agents against Granzyme B, a key biomarker for immuno-oncology. This collaboration recently moved into its final discovery stage prior to GE Healthcare assuming responsibility for further pre-clinical development.
Following a fully subscribed placement and rights issue raising A$8.1 million, AdAlta is well placed to progress AD-214 through Phase I clinical studies in patients during 2021, opening up a first potential partnering window for this asset. During that period, AdAlta also expects to expand its internal pipeline by commencing discovery on two new targets, and expanding its external pipeline with a further collaboration agreement.
AdAlta is open to discussions with potential licensees of AD-214, biopharmaceutical companies seeking to use i-bodies as novel targeting moieties for their favourite and most challenging targets and potential investors.
AdAlta’s proprietary i-body technology platform is being used to solve challenging drug targeting problems, generating a new class of single domain antibody protein therapeutics with the potential to treat some of today’s most challenging medical conditions. The i-body technology mimics the shape and stability of a unique and versatile antigen-binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with important but previously difficult to access targets such as G-protein coupled receptors (GPCRs). AdAlta’s i-bodies are the first fully human single domain antibodies and the first single domain antibodies utilising the shark motif to reach clinical trials.
AdAlta’s strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates, primarily against GPCRs implicated in fibrosis, inflammation and cancer; and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.
AD-214 is AdAlta’s lead i-body enabled internal pipeline candidate and is currently in Phase 1 clinical trials. AD-214 is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high unmet medical need.
AdAlta’s external pipeline collaborations include an agreement with GE Healthcare to discover i-bodies as diagnostic imaging agents against Granzyme B, a key biomarker for immuno-oncology. This collaboration recently moved into its final discovery stage prior to GE Healthcare assuming responsibility for further pre-clinical development.
Following a fully subscribed placement and rights issue raising A$8.1 million, AdAlta is well placed to progress AD-214 through Phase I clinical studies in patients during 2021, opening up a first potential partnering window for this asset. During that period, AdAlta also expects to expand its internal pipeline by commencing discovery on two new targets, and expanding its external pipeline with a further collaboration agreement.
AdAlta is open to discussions with potential licensees of AD-214, biopharmaceutical companies seeking to use i-bodies as novel targeting moieties for their favourite and most challenging targets and potential investors.
Ticker:
1AD
Exchange:
ASX
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Australia
Year Founded:
2006
Main Therapeutic Focus:
Platform for Therapeutics
Lead Product in Development:
AD-214
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
One
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
